However, BC patients with a high percentage of SLC14A1 CAF in their tumors exhibit adverse effects independent of cancer stage and less effective neoadjuvant chemotherapy, as IFN therapy is usually used in combination with surgical treatment, conventional chemotherapy or immunotherapy (70,71). The gene discussed is SLC14A1; the disease is breast cancer.